Shelter Pharma Limited has secured a noteworthy international order worth $1,41,600 from Taha Drugs & Chemicals Co. Ltd, a Sudan-based pharmaceutical entity. The company announced this development through a regulatory filing under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.

Order Details and Specifications

The secured order encompasses Joemega Capsule 3*10 Strips (BOX), representing a fixed-cost contract with the international client. The order details are structured as follows:

Regulatory Compliance and Transaction Structure

The company has confirmed that this international order maintains full regulatory compliance and transparency. Key compliance aspects include:

• The transaction does not fall within related party transactions
• Promoters and promoter group companies have no interest in the awarding entity
• The contract represents an arm's length transaction with the Sudan-based client
• Full disclosure has been made as per SEBI regulations

Company Profile and Market Position

Shelter Pharma Limited operates as a leading pharmaceutical and nutraceutical company with a focus on research, innovation, and quality standards. The company maintains state-of-the-art facilities and employs world-class expertise to deliver products adhering to industry standards. Their product portfolio spans pharmaceuticals and nutraceuticals, with a mission to provide accessible healthcare solutions globally.

The company's commitment to ethical practices and innovation has established its reputation as a trusted name in the pharmaceutical industry. This international order from Sudan demonstrates the company's expanding global reach and market acceptance of its pharmaceutical products.

Shelter Pharma has officially announced the launch of D3 Cure Capsules through a press release dated December 15, 2025, marking a significant expansion of its nutraceutical portfolio. The pharmaceutical company, with six decades of experience in natural healing, is strategically positioning itself to tap into the rapidly growing international vitamin D supplementation market.

Company Heritage and Vision

Shelter Pharma has spent the last six decades championing natural healing, guided by principles of tradition, integrity, and continuous progress. Since its humble beginning in 1965, the company has grown with a deep commitment to nature, blending traditional wisdom with a modern, forward-looking approach. The company combines extensive research and development with state-of-the-art technology while remaining dedicated to the natural way of healing.

Product Launch Details

The D3 Cure Capsules represent Shelter Pharma's strategic entry into addressing vitamin D deficiency, one of the most common nutritional deficiencies globally. The primary benefit of these capsules is the prevention and treatment of vitamin D deficiency, playing a crucial role in helping the body absorb calcium and phosphorus essential for maintaining overall health.

Comprehensive Health Benefits

The D3 Cure Capsules provide several significant health benefits across multiple body systems. The product supports bone health by aiding calcium absorption, helping maintain strong and healthy bones while reducing fracture risk. It is specifically used to manage conditions like osteoporosis, osteomalacia, and rickets in children.

Strategic Market Positioning

This launch is part of Shelter Pharma's comprehensive strategy to expand its nutraceutical portfolio and strengthen its presence in the wellness and preventive healthcare segment. The company believes the launch of D3 Cure Capsules will contribute positively to its growth prospects and reinforce its commitment to providing high-quality, science-backed nutritional solutions.

The company continues to focus on building a diverse portfolio of high-quality, accessible wellness products that cater to evolving consumer needs. As it deepens its presence in the nutraceutical sector, Shelter Pharma is positioned to deliver sustained growth, strengthen brand equity, and create long-term value for customers, partners, and investors alike.